These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27918774)

  • 41. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children.
    Iskedjian M; Haschke F; Farah B; van Odijk J; Berbari J; Spieldenner J
    J Med Econ; 2012; 15(2):394-408. PubMed ID: 22171936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis.
    Chiang C; Eichenfield LF
    Pediatr Dermatol; 2009; 26(3):273-8. PubMed ID: 19706087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of a moisturizer containing a pseudo-ceramide and a eucalyptus extract for Japanese patients with mild atopic dermatitis in the summer.
    Mori K; Seki T; Kaizu K; Takagi Y; Miyaki M; Ishizaki C; Katayama I
    J Cosmet Dermatol; 2019 Jun; 18(3):850-856. PubMed ID: 30084152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effective Primary Prevention of Atopic Dermatitis in High-Risk Neonates via Moisturizer Application: Protocol for a Randomized, Blinded, Parallel, Three-Group, Phase II Trial (PAF Study).
    Inuzuka Y; Yamamoto-Hanada K; Pak K; Miyoshi T; Kobayashi T; Ohya Y
    Front Allergy; 2022; 3():862620. PubMed ID: 35769566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness study of pediatric atopic dermatitis in Asia: atopiclair vs. regular emollient (AD-ATOP).
    Tang MB; Leong KF; Ou LS; Munasir Z; Parekh PR; Azmi S; Low WH; Goh A
    J Drugs Dermatol; 2015 Feb; 14(2):169-75. PubMed ID: 25689812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis.
    Zhong Y; Samuel M; van Bever H; Tham EH
    Allergy; 2022 Jun; 77(6):1685-1699. PubMed ID: 34591995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial.
    Wirén K; Nohlgård C; Nyberg F; Holm L; Svensson M; Johannesson A; Wallberg P; Berne B; Edlund F; Lodén M
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1267-72. PubMed ID: 19508310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study.
    Simpson E; Trookman NS; Rizer RL; Preston N; Colón LE; Johnson LA; Gottschalk RW
    Pediatr Dermatol; 2012; 29(5):590-7. PubMed ID: 22775151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A web-based survey on the behavior of moisturizer used in adults with and without atopic dermatitis in Thailand.
    Tuchinda P; Chularojanamontri L; Rujitharanawong C; Pochanapan O; Kulthanan K
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):246-252. PubMed ID: 35598192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age.
    Ellis CN; Kahler KH; Grueger J; Chang J
    Am J Clin Dermatol; 2006; 7(2):133-9. PubMed ID: 16605293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.
    Lenoir-Wijnkoop I; van Aalderen WM; Boehm G; Klaassen D; Sprikkelman AB; Nuijten MJ
    Eur J Health Econ; 2012 Feb; 13(1):101-10. PubMed ID: 21165666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bath emollients for atopic eczema: why use them?
    Drug Ther Bull; 2007 Oct; 45(10):73-5. PubMed ID: 17928284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic Burden of Atopic Dermatitis in High-Risk Infants Receiving Cow's Milk or Partially Hydrolyzed 100% Whey-Based Formula.
    Bhanegaonkar A; Horodniceanu EG; Ji X; Detzel P; Boguniewicz M; Chamlin S; Lake A; Czerkies LA; Botteman MF; Saavedra JM
    J Pediatr; 2015 May; 166(5):1145-1151.e3. PubMed ID: 25919724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Costs and Cost-effectiveness of Collaborative Care for Adolescents With Depression in Primary Care Settings: A Randomized Clinical Trial.
    Wright DR; Haaland WL; Ludman E; McCauley E; Lindenbaum J; Richardson LP
    JAMA Pediatr; 2016 Nov; 170(11):1048-1054. PubMed ID: 27654449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.